Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: Final results

Paul E. Sax; Camlin Tierney; Ann C. Collier; Eric S. Daar; Katie Mollan; Chakra Budhathoki; Catherine Godfrey; Nasreen C. Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F. Rooney; Belinda Ha; William C. Woodward; Judith Feinberg; Karen Tashima; Robert L. Murphy; Margaret A. Fischl

Journal ArticleOPEN ACCESS

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: Final results

Sax P
Tierney C
Collier A
et al.

Journal of Infectious Diseases (2011) 204(8) 1191-1201

DOI: 10.1093/infdis/jir505

163Citations

126Readers

Abstract

Background. AIDS Clinical Trials Group A5202 compared blinded abacavir/lamivudine (ABC/3TC) to tenofovir DF/emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in human immunodeficiency virus (HIV)-infected treatment-naive patients, stratified by screening HIV RNA (

Cite

CITATION STYLE

APA

Sax, P. E., Tierney, C., Collier, A. C., Daar, E. S., Mollan, K., Budhathoki, C., … Fischl, M. A. (2011). Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: Final results. Journal of Infectious Diseases, 204(8), 1191–1201. https://doi.org/10.1093/infdis/jir505

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: Final results

Abstract

Cite

Register to see more suggestions